IL10 as Cancer Biomarker by Gonzalez-Garza, Maria Teresa et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
125,000 140M
TOP 1%154
5,000
1Chapter
IL10 as Cancer Biomarker
Maria Teresa Gonzalez-Garza, Delia Elva Cruz-Vega  
and Carmen Maldonado-Bernal
Abstract
Chronic inflammation can trigger events that would induce the malignant trans-
formation of cells and carcinogenesis. Cytokines play a crucial role and can control 
the development and multiplication of cancerous cells. However, clinical data pres-
ent controversy about the participation of these proteins in the establishment and 
development of cancer. Interleukin 10 (IL-10), a potent anti-inflammatory cytokine, 
has been the subject of multiple studies. Several studies have reported that IL-10 has 
pro- and antitumor effects. Elevated levels of IL-10 are associated with increased 
tumor growth with poor prognosis and drug resistance. However, this cytokine has 
both tumor-promoting and tumor-inhibiting properties. In vitro and in vivo studies 
report mechanisms by which IL-10 expression downregulates class I, which results 
in the control of the metastatic disease. IL-10 also inhibits tumorigenesis via down-
regulation of other cytokines. The variation observed could be the result of concen-
tration ranges of this protein, genetic polymorphism, or both. The value obtained 
may serve as a biomarker indicative of tumor development and its prognosis.
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1. Introduction
The immune system is responsible for monitoring and getting rid of molecules 
or cells outside the body that can be potentially malignant. This system is con-
stituted by cells that can act by themselves or the synthesis of molecules capable 
of inducing the destruction of strange agents or invading cells. In addition, these 
cells synthesize proteins called cytokines, which are not only capable of destroying 
invading cells; they activate other cells of the same immune system, which makes 
the system efficient. In a coordinated way, the synthesis of anti-inflammatory 
cytokines begins that will stop the inflammatory process and prevent the damage 
from spreading in healthy tissue. In the case of cancer, the cells will have nonnormal 
characteristics due to the changes they undergo during their transformation. The 
immune system works to eliminate these cells; however, for reasons not well estab-
lished yet, at some point, the immune system fails, and the malignant cells survive 
and establish [1]. Even when the production of anti-inflammatory cytokines is 
present, the levels of pro- and anti-inflammatory cytokines have an imbalance that 
prevents completing the final objective. An increase of anti-inflammatory cyto-
kines, such as interleukin 10 (IL-10), has been associated with a poor prognosis and 
considered as a biomarker for cancer disease. This chapter presents evidence that 
shows alterations in the serum levels of IL-10 in cancer patients, the participation of 
the cancerous tumor in the synthesis of this cytokine, and its possible relationship 
with polymorphisms in the gene promoter, the gene of this protein.
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2. Interleukin 10 (IL-10)
IL-10 is an important regulatory cytokine with a potent anti-inflammatory 
effect. In humans, it is encoded by the IL10 gene [2]. It presents polymorphisms 
(SNPs), most of them within the promoter regions, and has been proposed as 
responsible for the altered function, by dysregulating their expression. Several 
groups report associations between polymorphism and cancer risk [3–7]. It is a 
helical cytokine and exists in solution predominantly as a homodimer, composed 
of two polypeptide chains of 160 amino acids, each with a molecular weight of 
20,6419 kD [8].
IL-10 was initially thought to be produced only by T helper (Th2) cells but is 
now known to be made by a variety of cell types [9]. It is primarily produced by 
monocytes upon PD-1 triggering in these cells and, to a lesser extent, lymphocytes 
type 2 T helper cells (TH2), mast cells, CD4+CD25+Foxp3+ regulatory T cells, and 
in a specific subset of activated T cells and B cells (Figure 1) [10]. IL-10 expression 
is minimal in unstimulated tissues and seems to require triggering [11].
Cytokine signals are generated through a receptor complex consisting of two 
IL-10 receptor-1 and two IL-10 receptor-2 proteins. After IL-10 binding, it induces 
STAT3 signaling via the phosphorylation of the cytoplasmic tails of IL-10 receptor 1 
+ IL-10 receptor 2 by JAK1 and Tyk2, respectively (Figure 2) [12, 13].
IL-10 expression is regulated at the transcriptional and posttranscriptional lev-
els. Extensive IL-10 locus remodeling in monocytes upon the stimulation of Toll-like 
receptor (TLR) or Fc receptor pathways was described. Induction involves ERK1/2, 
p38, and NF-κB signaling and transcriptional activation via promoter binding of 
Figure 1. 
IL-10R homodimers bind to form in a tetrameric heterodimer after IL-10 binds to its receptor α. It downstream 
signaling through STAT3 until target genes.
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the transcription factors NF-κB and AP-1; other regulation as a complex of multiple 
transcriptional factors has been described, such as GATA-3, E4BP4, MAF, and Blimp 
[14, 15]. These reports are allowing the possibility that transcriptional regulatory 
machinery could be specific to certain cell types [16, 17]. In addition, the regulation 
of IL-10 production depending on the TLR2 or TLR4-stimulated in BM-derived 
macrophages presents different stability profiles for the IL10 mRNA [18].
It has the ability to inhibit activation and effector function of T cells, monocytes, 
and macrophages. It regulates the growth and differentiation of several cells such 
as B cells, NK cells, cytotoxic, and helper T cells, as well as mast cells, granulocytes, 
dendritic cells, keratinocytes, and endothelial cells (Figure 1).
Discovered in 1991, IL-10 was initially reported to suppress cytokine secretion, 
antigen presentation, and CD4+ T cell activation. IL-10 is crucial for controlling 
these T-cell responses, as IFNγ [19–22]. Further investigations have shown that 
IL-10 predominantly inhibits the synthesis of the pro-inflammatory cytokines IL-1, 
IL12, tumor necrosis factor (TNFα), and gamma Interferon (IFNγ) by stimulated 
monocytes/macrophages [23–25]. IL-10 is crucial for controlling these T-cell 
responses, as IFNγ-secreting and blocking proliferation [22, 26–28].
The pivotal role of autocrine IL-10 and the interaction with CD28 in the induc-
tion of T cell are to initiate peripheral tolerance as an immunoregulatory mecha-
nism controlling antigen-specific T cell responses [21].
In addition, several effects have been reported: it downregulates the expression 
of Th1 cytokines, MHC class II antigens, dendritic cells, and co-stimulatory mol-
ecules on macrophages [29].
Biphasic effects have been reported on B cells. It prevents apoptosis in germinal 
B cells but induces apoptosis on B-chronic lymphocytic leukemia cells, enhances 
proliferation induced by CD40L, and promotes differentiation of B cells to become 
plasma cells secreting IgM, IgG, and IgA immunoglobulins [30–34].
IL-10 appears to have considerable importance in the development of human 
cancer and its immune escape. These have suggested that it could serve as a bio-
marker for prognostic diseases or as a target for treatment. Two factors should be 
considered: high levels of this cytokine in the system, and genetic polymorphisms.
Figure 2. 
After antigenic stimulus on cells from innate and adaptive system, the IL-10 is expressed from these cells. To 
avoid severe danger from pro-inflammatory cytokines and reactive radicals, IL-10 acts as anti-inflammatory 
cytokine by blocking its expression.
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3. IL-10 serum levels on cancer patients
Considering their possible role in the development and establishment of 
malignant cells, the first studies conducted to detect serum IL-10 levels in cancer 
patients, reported a higher concentration than in healthy subjects. In melanoma 
patients with lymph node metastases, stages III and IV showed significantly high 
concentration with respect to a healthy subject. In vitro determination performed 
on the supernatant of primary malignant melanoma cultures, IL-I0 mRNA, and 
protein was expressed. Later, in a meta-analysis that included melanoma patients, 
high expression of serous IL-10 leads to an adverse survival and correlated with 
worse outcomes in cancer patients [35–39].
On serum samples of 90 patients with gastric cancer, high IL-10 levels were 
associated with a worse prognosis independent of the gastric-stage patients and 
pancreatic cancer [40]. Similar observations were reported on another group of 
patients with a pancreatic and gastric cancer stage (IV). In the same study, patients 
with colon and renal carcinoma IL-10 levels did not significantly differ from con-
trols [41]. In vitro study, supernatants of pancreatic tumors primary cultures, high 
concentration of IL-10 was detected [42].
Similar clinical findings on sera and tissues samples from lung cancer patients 
were report; samples with high levels were found on patients in stages III and IV, 
and less in stages II and I. The increased IL-10 levels correlate with a poor prognosis. 
On lung tumor tissues samples from those patients, IL10 concentration showed than 
the higher expression, presented lower survival rates [43].
Samples from breast cancer from patients, who underwent surgery as well as 
peritumoral normal breast tissue, were analyzed. Correlation between the IL-10 
expressions of breast cancer tissue showed poor prognosis. No IL-10 was detected 
on normal tissue samples [44]. Determination of IL-10 on patients with breast 
cancer and early breast cancer showed that it could be usefully associated with 
other cytokines as biomarkers to discriminating advanced cancer, reported that 
IL-10 is significantly upregulated. These data could be used discerning between the 
two stages. [45].
Hodgkin’s disease presented sera elevated IL-10 levels on range 4.5–225.6 pg/
ml, suggesting that IL-10 could be an independent prognostic factor and correlates 
to poor survival [46]. Lymph nodes from pediatric patients with Hodgkin’s disease 
express high levels of IL-10 mRNA where there were associated with an unfavorable 
prognosis [47, 48]. For the study of sera levels in 153 patients with Non-Hodgkin’s 
disease, IL-10 was detectable with a similar frequency in all subtypes and all clinical 
stages. Nevertheless, high levels correlate with poor prognosis. Patients with stage 
IV disease and detectable serum IL-10 had a particularly poor prognosis [49, 50]. 
Additional information on sera levels of IL-10 is shown in Table 1.
IL-10 protein or mRNA appears to be an important component of the tumor 
micro-environment in a range of human cancer types, as renal cell carcinoma [68]. 
The role of macrophages in the regulation of tumor cell proliferation, invasion, 
angiogenesis, or immune control does not always have a positive effect; in fact, 
it has shown a negative effect. The secretion of IL-10 inhibits the inflammatory 
response [69–72] and also has been suggested that the detection of IL-10 into and 
surrounding the tumor may be derived directly from the tumor cells; in vitro studies 
reveal that melanoma cells themselves are the primary origin of IL-10 in tumor 
specimens in vivo [35]. Nevertheless, Mocellin et al. report evidence about immu-
nostimulating anticancer properties, suggesting IL-10 over-expression within the 
tumor micro-environment and it may catalyze cancer immune rejection [73].
IL-10 and IL10R were quantified in sera and surgical specimens, although no 
significant serum IL-10 elevation was found. On surgical lung tumor cells, IL-10 
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expression was considered as a prognostic factor on nonsmall-cell lung cancer 
surgical specimens. In addition to an immunohistochemistry study on human lung 
surgery, a positive correlation between IL-10 and IL-10 receptor expressions was 
related to the lung tumor diameter. Interestingly, IL-10R was mainly expressed on 
the surface of Foxp-3þ T-regulatory lymphocytes infiltrating the tumor [74, 75].
4.  IL10 polymorphims related to the development and prognosis of 
cancer
Single nucleotide polymorphisms (SNPs) has been described on IL10 promoter, 
where adenine was substituted by guanine at −1082 bp (rs1800896). Thymine was 
replaced by cytosine at −819 bp (rs1800871) and adenine by cytosine at −592 bp 
(rs1800872). All of those contribute to the variation in protein expression [76]. The 
IL10 production have a hereditary component estimated in 75%, suggesting that 
Disease Patients IL-10 levels Healthy donor References
Melanoma 15–480 pg/ml <3.0 pg/ml [35]
8.75 pg/ml <3.0 pg/ml [39]
24.3 ng/ml 3.4 ng/ml [41]
Gastric cancer 6.3 ng/ml 3.4 ng/ml [41]
12.5 pg/ml 4.0 pg/ml [40]
27.52 pg/ml <12 np/ml [51]
19.6 pg/ml 9.2 pg/ml [52]
>21.0 pg/ml <3.0 pg/ml [53]
Pancreatic cancer 6.8 ng/ml 3.4 ng/ml [41]
>10.0 pg/ml ND [54]
>9.8 pg/ml 3.0 pg/ml [55]
Colorectal cancer 97.36 ng/l 24.53 ng/l [56]
16.09 pg/ml 5.1 pg/ml [57]
Hepatic cancer 12 pg/ml 6.3 pg/ml [58]
Hodgkin lymphoma 61.5 pg/ml No detectable [46]
>10 pg/ml 7.1 pg/ml [59]
>10 pg/ml ND [60]
>10 pg/ml ND [61]
26.79 pg/ml ND [62]
Non-Hodgkin lymphoma >7.98 pg/ml <5.0 pg/ml [50]
Lung cancer >38.16 pg/ml 32.55 pg/ml [43]
21.4 pg/ml 9.2 pg/ml [63]
Multiple myeloma 201.96 pg/ml ND [64]
2.39 ± 0.82 ng/ml (0.34 ± 0.15 ng/ml) [65]
B-cell lymphoma 26.0 pg/ml 18.0 pg/ml [66]
Chronic lymphocytic leukemia 74 pg/ml <13.68 pg/ml [67]
Table 1. 
Determination of IL-10 levels in serum from cancer patients.
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clinical outcome imparted by IL10 genetic variants may be mediated by effects on 
the tumor micro-environment composition or modulation [47]. The possibility that 
SNPs participate in the development, establishment, and the prognosis of cancer 
has been investigated by numerous research groups and includes several group 
malignances.
Eastern European patients with breast cancer, IL10 −1082A > G, −819 T > C, 
−592A > C polymorphisms, and phased haplotypes have not revealed a prognostic 
value [77]. Nevertheless, another study report 592C > A polymorphisms could 
modify disease-free and overall survival in women with lymph node-positive 
breast cancer [78]. In a Chinese Han population study, the −1082AA genotype was 
associated with a significantly increase risk of lymph node involvement and larger 
tumor size at the time of diagnosis [79]. After meta-analysis, it showed that IL10 
rs1800896 and rs1800871 polymorphisms had no association with breast cancer 
risk, while rs1800872 polymorphism had a decreased risk of breast cancer in 
Caucasians [3]. However, another meta-analysis suggests that IL10 rs1800871 and 
rs1800872 polymorphisms might contribute to breast cancer susceptibility in the 
overall population, but not by ethnicity [6].
Chinese men, diagnostic with prostate cancer, do not show significant differ-
ences in (−1082A/G, −819 T/C, and −592A/C) SNPs between patients and control 
subjects [80]. Meta-analysis performed with a Caucasian and Asiatic population 
suggests that there is no association between IL10 gene rs1800896, rs1800871, 
and rs1800872 polymorphisms and prostate cancer [81]. A study looking for the 
participation of variant alleles at both −819 and −592 polymorphisms was modestly 
associated with the advanced stages of prostate cancer [82, 83]. Other meta-analysis 
reports that rs1800896 polymorphism is associated with a decreased risk of prostate 
cancer [84].
In a meta-analysis including 26 studies designed to search the risk of skin cancer 
and IL10 polymorphism, the results show that there is not a significant association 
of −1082G > A or −592C > A and risk to skin cancer. Nevertheless, it suggested 
a potential association between −819C > T polymorphism and decreased risk of 
skin cancer [38]. A meta-analysis carried out for possible association between 
polymorphism and melanoma did not find an association between skin cancer risk 
and the −592A/C or IL-10-1082G/A. However, there was a correlation between IL10 
−819T/C polymorphisms and skin cancer [85].
Association between IL10 −1082A/G, −592C/A, and −819T/C gene polymor-
phisms and risk of lung cancer was also investigated by meta-analysis, but until 
now, there are inconsistent results: on Asian populations, IL10 −1082A/G and 
−819T/C polymorphisms might have a significant association with the risk of lung 
cancer [86]. Another meta-analysis suggests that the polymorphism associated with 
a risk factor for lung cancer was IL10 −592A > C polymorphism, especially among 
Asians and Caucasians. In contrast, the IL10 −819 T > C and −1082A > G polymor-
phisms are not significantly associated with an increased risk of lung cancer [87].
Cervical cancer associated with a polymorphism at this time is not conclusive: 
−1082 polymorphism was suggested as a marker of genetic susceptibility to cervical 
cancer among Japanese women but was not significantly increased in Zimbabwean 
women or Korean women [88]. In a meta-analysis, including 17 publications of 
Asian, African, and Caucasian populations, it did not find a significant association 
between the polymorphism and cervical cancer risk [89]. Other meta-analysis 
looking for association between −1082 G/A polymorphism and cervical cancer risk, 
including the same population, report as well that there is no association [90].
Association between rs1800896 polymorphism and head and neck cancer risk 
and its clinical stages in Caucasian and Asiatic evaluated by meta-analysis gave 
a significant association with head and neck cancer risk but not with the clinical 
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Disease Population Polymorphism Association Reference
Breast cancer Eastern European IL10 −1082A/G, IL10 
−592A, IL10 −819C
No prognostic value [77]
Eastern European IL10 −592C > A Associated with 
survival
[78]
Chinese Han IL10 −1082AA Associated with 
cancer risk
[79]
Chinese Han rs1800896, rs1800871 No associated with 
cancer risk
[3]
Caucasian rs1800872 Associated with 
cancer risk
[3]
Prostate Chinese men study IL10 −1082A/G, IL10 
−592A/C, IL10 −819 T/C
No associated with 
cancer risk
[80]
Caucasian, African-
Americans, and 
Asiatic
rs1800896 Associated with 
reduced cancer risk
[84]
Caucasian and 
Asiatic
rs1800896, rs1800871, 
rs1800872
No association with 
risk cancer
[81]
Caucasian, African-
Americans, and 
Asiatic
IL10-1082 A4G, IL10-819 
C4, IL10-592 C4A
No association with 
cancer risk
[82]
Caucasian and 
Asiatic
IL10--592A > C No association with 
cancer risk
[83]
Skin cancer Caucasian, African-
Americans, and 
Asiatic
IL10 −1082A/G, IL10-
592A, IL10-819C
No associated with 
cancer skin risk
[82]
Caucasian, African-
Americans, and 
Asiatic
IL10 −592A/C, IL10 
−1082G/A
No associated with 
cancer risk
[85]
Lung cancer Asiatic IL10 −1082A/G, IL10-
592A, IL10-819C
Associated with 
cancer risk
[86]
Caucasian IL10 −1082A/G, IL10-
592A, IL10-819C
No association with 
cancer risk
[86]
Caucasian IL10 −592A > C Associated with 
cancer risk
[87]
Caucasian and 
Asiatic
IL10 −819 T > C, IL10 
−1082A > G
No associated with 
cancer risk
[87]
Cervix cancer Japanese women IL10 −1081 Associated with 
cancer risk
[88]
Zimbabwean women 
and Korean women
IL10 −1082 No associated with 
risk
[88]
Caucasian, African-
Americans, and 
Asiatic
IL10 −1082A > G No associated with 
risk
[89]
Caucasian, African-
Americans, and 
Asiatic
IL10 −1082 G/A No associated with 
cancer risk
[90]
Head and 
neck cancer
Caucasian and 
Asiatic
rs1800896 Associated with 
cancer risk
[91]
Caucasian, and 
Asiatic
IL10 −1082A > G, IL10 
−819 T > C
Associated with 
cancer risk
[92]
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stages [91]. Other analysis reports significant associations between the IL10 
−1082A > G and IL10 −819 T > C polymorphism and increased risks of head and 
neck cancer similar population [92].
Other studies on the relation between risk or prognosis polymorphisms in cancer 
have been performed. In there, a possible association with gastric cancer showed 
a significant association with IL10-819 on the Mexican population. Nevertheless, 
no significant association was found for IL10 −592C/A (rs1800872) and IL10 
−1082A/G (rs1800896) [93]. Looking for a possible predispose to oral squamous 
cell carcinoma (−592), A/C polymorphism was significantly associated with 
reduced risk [94]. In colorectal cancer IL10 −819 T > C, polymorphism was associ-
ated with significantly increased risk [95].
In a clinical study with child Hokdkin disease, −1082GG genotype was associ-
ated with lower IL10 mRNA expression. Nevertheless, genotypes of the −592 SNP 
showed no association with IL10 mRNA expression. However, −1082AACAG 
genotypes, ATA haplotype, and the presence of the −592AA genotype were associ-
ated with unfavorable prognosis [47, 96].
Genotypic variants of IL10 (−1082G/A) polymorphism in adult Sudanese 
patients with acute myeloid leukemia were investigated as a possible risk factor. In 
there, no association between IL10 (−1082G/A) and acute myeloid leukemia was 
detected [7]. Nevertheless, in the Egyptian population, −819 polymorphism was 
associated with enhanced risk [97]. In the Chinese population, the −819A allele 
frequencies in the AML group were higher than in the controls [98]. In pediatric 
patients, Classical Hodgkin lymphoma −1082AA/AG, −592CC genotypes, and ATA 
haplotype were associated with unfavorable prognosis; interestingly, −1082 was 
associated with low IL10 mRNA expression [46].
Unfortunately, to date, the results are controversial; the relationship of polymor-
phism with the presence of cancer and/or the possible risk of developing cancer is 
shown in Table 2.
Disease Population Polymorphism Association Reference
Gastric cancer Mexican population IL10 −819 Associated with risk [93]
Mexican population IL10 −592C/A, IL10 
−1082A/G
No associated with 
risk
[93]
Oral mucosa 
cancer
Indian population IL10-592 A/C Associated with 
cancer risk
[94]
Colorectal 
cancer
Caucasian and 
Asiatic
IL10819T > C Associated with 
cancer risk
[95]
Caucasian and 
Asiatic
rs1800871 rs1800872 No associated with 
cancer risk
[95]
Caucasian and 
Asiatic
IL10 −1082A > G, IL10 
−592C > A
No associated with 
cancer risk
[95]
Pediatric 
Hodgkin’s 
disease
Caucasian IL10-592AA Pronostic marker [96]
Brazilian IL10 −1082GG Unfavorable 
prognosis
[47]
Acute myeloid 
leukemia
Egyptian IL10-819 Associated with risk [97]
Chinese Han IL-10-819, −592 Associated with risk [98]
Sudanese IL10 −1082G/A Associated with risk [7]
Table 2. 
Relationship of IL10 polymorphism and cancer risk.
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5. Conclusions
High concentrations of IL-10 in the serum of cancer patients seem to correspond 
not only to the expression of this protein by immune cells. The evidence shows that 
the cancer cell is capable of synthesizing it, which would cause an imbalance in the 
homeostasis of the immune system.
Besides, the presence of polymorphisms suggested the possibility that some of 
them could be involved in the regulation of the activity of IL10; this gave rise to 
numerous studies seeking opportunities to explore for cancer risks or implications 
in the development, establishment, and survival of the cancer cell. The relation-
ship between polymorphisms and the risk and prevalence of different types of 
cancer had evaluated by meta-analysis. Unfortunately, until now, the results are not 
conclusive.
Nevertheless, the fact is that IL-10 can exert the antitumor effect by mechanisms 
such as the activation of natural killer cells (NK), lymphocytes T, macrophages, 
and nitric oxide; its high concentration shows the deregulation of the immune 
system, where a high level of IL10 allows the tumor to escape. Nevertheless, the fact 
that IL-10 can exert the antitumor effect by mechanisms such as the activation of 
natural killer cells, lymphocytes T, macrophages, and nitric oxide results controver-
sial. Its high concentration induces the deregulation of the immune system, where 
a high level of IL-10 allows the tumor escape. In some cases, it could be propose as a 
biomarker for patient lifespan or chemotherapy respond.
Because of this, it is essential to study not only the mechanisms that allow this 
high expression of interleukin IL-10, but its effect on tumor cells and also. It is 
important to consider its relationship with other cytokines.
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